Survival post-treatment for childhood malignancy is now in excess of 70%. Hence female reproductive potential following treatment must be addressed. Issues concerning subsequent uterine and ovarian function, fertility options and importantly the ethics and safety of treatment approaches are discussed herein.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.12968/hosp.2002.63.9.1946 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!